Minulet (Ethinylestradiol, Gestodene)

Ethinylestradiol is a synthetic estrogen that provides negative feedback to the hypothalamus‑pituitary axis, while gestodene is a progestin that activates progesterone receptors. Together they inhibit the secretion of LH and FSH, preventing follicular development and ovulation. The hormonal environment also thickens cervical mucus and alters the endometrium, reducing the chance of sperm penetration and implantation.

The dosage regimen for Minulet is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule, tablet strength and duration are individualized based on the patient’s medical history and treatment goals. Patients should follow the prescriber’s instructions precisely.

Minulet is contraindicated during pregnancy because it is intended to prevent conception, not to support an existing pregnancy. Women who become pregnant while taking the product should discontinue use and consult a healthcare provider. Regarding breastfeeding, combined oral contraceptives are generally not recommended during lactation, especially in the early postpartum period, due to potential effects on milk production and infant exposure.

To request Minulet, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation before finalising the order.

Minulet contains ethinylestradiol paired with gestodene, a third‑generation progestin that is associated with a lower incidence of androgenic side effects such as acne compared with earlier‑generation progestins. Compared with products using levonorgestrel, Minulet may have a slightly different bleeding pattern but offers similar contraceptive efficacy. Choice of product depends on individual risk factors, tolerability and physician preference.

Minulet tablets should be stored at ambient temperature, below 25 °C (77 °F), in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use it after the expiry date printed on the packaging. Avoid storing in bathrooms or other humid environments to maintain product stability.

Minulet is taken orally, usually once daily at the same time each day. The typical regimen consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should swallow the tablet whole with water and should not skip or double doses; if a dose is missed, they should follow the guidance provided by their healthcare professional.

The most serious risks of Minulet involve thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke or myocardial infarction, particularly in women who smoke, have hypertension, or possess a personal or family history of clotting disorders. Other rare but severe reactions include severe liver disease, gallbladder disease and life‑threatening allergic reactions. Patients should seek immediate medical attention if they experience unexplained chest pain, severe headache, visual changes or swelling of the limbs.

Minulet is contraindicated in women who are pregnant or breastfeeding, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected estrogen‑dependent tumors, or are smokers over 15 cigarettes per day. It should also be avoided in individuals with known hypersensitivity to ethinylestradiol, gestodene or any tablet excipients. Patients with these conditions should discuss alternative contraceptive options with their healthcare provider.